0624 Anticataplectic Efficacy of Pitolisant, the First Potent and Highly Selective Histamine H3-Receptor Antagonist/Inverse Agonist. (27th April 2018)

• Record Type: Journal Article
• Authors: Thorpy, M; Schwartz, J; Lecomte, J; Caussé, C; Dayno, J M
• Is Part Of: Sleep. Volume 41(2018)Supplement 1
• Page Start: A232
• Page End: A232
• Publication Date: 2018-04-27
• Subjects: Sleep -- Physiological aspects -- Periodicals; Sleep disorders -- Periodicals; Sommeil -- Aspect physiologique -- Périodiques; Sommeil, Troubles du -- Périodiques; Sleep disorders; Sleep -- Physiological aspects; Sleep -- physiological aspects; Sleep Wake Disorders; Psychophysiology; Electronic journals; Periodicals; 616.8498
• DOI: 10.1093/sleep/zsy061.623
• Languages: English
• ISSNs: 0161-8105

Abstract

Abstract: Introduction: Pitolisant, the first potent and highly selective histamine H3-receptor antagonist/inverse agonist, has demonstrated efficacy in reducing excessive daytime sleepiness (EDS) in narcolepsy and cataplexy in narcolepsy. In this report, the anticataplectic efficacy results of pitolisant are summarized from five phase 2 and 3 studies. Methods: Weekly Rate of Cataplexy (WRC) attacks was estimated based on daily diary reporting by adults with narcolepsy treated with pitolisant once daily (dose up to 36 mg). WRC was the primary endpoint in phase 3 (HARMONY-CTP, HARMONY II) studies and a secondary endpoint in phase 3 (HARMONY I and III) and phase 2 (P6-06) studies. In some studies, selective serotonin reuptake inhibitors and sodium oxybate were permitted. Results: In a 7-week, placebo-controlled, phase 3 study (n=105), pitolisant reduced WRC by 75%, from 9.15 to 2.27 ( P <0.0001 vs placebo). Significant reduction of WRC was confirmed in the subgroup of patients presenting with WRC >15 ( P <0.0001 vs placebo). In an 8-week, placebo- and active-controlled, phase 3 study (n=76), pitolisant reduced WRC by 62% ( P =0.034 vs placebo). In a long-term, open-label, phase 3 study (n=104), pitolisant reduced total and partial WRC by 76% and 64%, respectively, after 12 months of treatment. In an open-label, phase 2 study (n=27), pitolisant reduced WRC by 40% ( P =0.024) after 1 month. In an 8-week, phase 3 study (n=15), WRC was reduced by 56% in the pitolisant-only subgroup and by 71% in the pitolisant + modafinil subgroup. Conclusion: Pitolisant demonstrated a potent anticataplectic effect (reduction by 60%-75% in placebo-controlled studies), which was consistent across all clinical studies and was maintained for ≥12 months. The anticataplectic effect of pitolisant, in combination with its efficacy in reducing EDS and favorable safety profile, indicates that pitolisant may be a new therapeutic option for patients with type 1 narcolepsy. Support (If Any): Study funded by Bioprojet, France.